SENTINEL Trial Shows Positive One-Year Data on Addition of Tysabri to Avonex

One-year data from the Phase III SENTINEL trial demonstrated that when Tysabri was added to Avonex in patients with relapsing forms of multiple sclerosis (MS), the annualized clinical relapse rate was reduced by 54 percent over the effect of Avonex alone.

In addition, these data, presented for the first time at a major medical meeting, demonstrated that the addition of Tysabri (natalizumab) to Avonex (Interferon beta-1a) resulted in significantly fewer new or newly enlarging T2-hyperintense lesions and gadolinium-enhancing lesions than Avonex alone, and that the proportion of Tysabri/Avonex patients who remained relapse-free was significantly higher than in the Avonex group.